ReviewProceedings of the American Thoracic Society2010
Mesenchymal stem cells modulate lung injury.
Review in Proceedings of the American Thoracic Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Allogeneic human umbilical cord-derived mesenchymal stem cells reduce lipopolysaccharide-induced inflammation and acute lung injury.American journal of translational research · 2020Article
- Transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) improves brain ischemia-induced pulmonary injury in rats associated to TNF-α expression.Behavioral and brain functions : BBF · 2016Article
- Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF).Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015Review
- Stem cells: innovations in clinical applications.Stem cells international · 2014Review
- Bone marrow mesenchymal stem cells ameliorates seawater-exposure-induced acute lung injury by inhibiting autophagy in lung tissue.Pathology research international · 2014Article
- Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation.Stem cells (Dayton, Ohio) · 2013Article
- A therapeutic role for mesenchymal stem cells in acute lung injury independent of hypoxia-induced mitogenic factor.Journal of cellular and molecular medicine · 2012Article
- Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing.Expert opinion on biological therapy · 2011Review
- Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis.BMC immunology · 2011Article
- Pregnancy-associated progenitor cells: an under-recognized potential source of stem cells in maternal lung.Placenta · 2011Review
- Epithelial interactions and local engraftment of lung-resident mesenchymal stem cells.American journal of respiratory cell and molecular biology · 2011Article
- Stem cells and cell therapies in lung biology and lung diseases.Proceedings of the American Thoracic Society · 2011Article
- Alveolar epithelial cell therapy with human cord blood-derived hematopoietic progenitor cells.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) have been shown to differentiate into a variety of mesenchymal cell types, including fibroblasts, myofibroblasts, osteoblasts, chondroblasts, adipocytes, and myoblasts, as well as epithelial cells. It has been shown that these cells can be recovered from bone marrow as well as umbilical cord blood, and they can be propagated, stored, and administered to animals and patients in clinical trials. It is clear that the cells engraft in the lung, and several laboratories have demonstrated an ameliorating effect in models of acute injury caused by LPS and in chronic lung injury induced by bleomycin and asbestos. However, it is not at all clear under what conditions these cells must be applied to provide an advantage and when using these cells might cause exacerbation of the lung injury. This brief review focuses on the biology of MSCs in vitro, how the cells have been used in some animal models, and the potential for their use in therapeutic strategies for diseases as diverse as lung cancer and interstitial fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.